BNTC · Benitec Biopharma Inc.

Benitec’s Q3 FY2026 financial results reflect disciplined expense management, with total operating expenses declining 11% year-over-year to $13.6 million, driven by a $1.5 million reduction in general and administrative costs and a $0.2 million dip in research and development spending—primarily tied to BB-301 clinical development for OPMD. The $11.9 million net loss ($0.24 per share) marks an improvement over the prior-year quarter’s $14.5 million loss ($0.38), aided by higher interest income ($1.6M vs. $0.8M) and modest foreign currency gains. Management emphasized clinical momentum: all six Cohort 1 patients completed 24-month follow-up with sustained low-dose BB-301 responses, while Cohort 2’s first two high-dose patients were safely treated and showed early evidence of deeper, disease-modifying efficacy—supporting the ongoing Phase 1b/2a trial’s progression toward pivotal study design discussions with the FDA mid-year. With $184.8 million in cash as of March 31, 2026—up sharply from $97.7 million a year earlier—the company reaffirmed its ability to fully fund BB-301 through pivotal study completion without near-term dilution. The upcoming oral presentation at ASGCT on May 15 and anticipated 2H-2026 interim data updates represent key near-term catalysts for investor sentiment, particularly given BB-301’s Orphan Drug and Fast Track designations and its potential as the first disease-modifying therapy for OPMD-related dysphagia.